Complexation study of the anticancer agent EO-9 with 2-hydroxypropyl- β-cyclodextrin

Drug Development and Industrial Pharmacy

Volumn 34, Issue 10, 2008, Pages 1130-1139

  Beijnen, J H ^a,b   Van Der Schoot, S C ^a   Nuijen, B ^a   Flesch, F M ^b   Gore, A ^c   Mirejovsky, D ^c   Lenaz, L ^c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Spectrum Pharmaceuticals   (United States)

Author keywords

Complexation; Cyclodextrin; EO 9

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; APAZIQUONE; ITRACONAZOLE; WATER;

AQUEOUS SOLUTION; ARTICLE; BLADDER IRRIGATION; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; FREEZE DRYING; INFRARED SPECTROMETRY; SCANNING ELECTRON MICROSCOPY; X RAY DIFFRACTION;

ANTINEOPLASTIC AGENTS; AZIRIDINES; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; INDOLEQUINONES; MICROSCOPY, ELECTRON, SCANNING; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 52949102189     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040801974261     Document Type: Article

References (29)

1. Arias, M. J., Moyano, J. R., Munoz, P., Gines, J. M., Justo, A., & Giordano, F. (2000). Study of omeprazole-gamma-cyclodextrin complexation in the solid state. Drug Dev. Ind. Pharm., 26, 253-259.
2. Bandi, N., Wei, W., Roberts, C. B., Kotra, L. P., & Kompella, U. B. (2004). Preparation of budesonide- and indomethacin-hydroxypropyl-beta- cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process. Eur. J. Pharm. Sci., 23, 159-168.
3. Beijnen J. H., Den Hartigh, J., & Underberg W. J. M. (1985). Qualitative aspects of the degradation of mitomycins in alkaline solution. J. Pharm. Biomed. Anal., 3, 71-79.
4. Connors, K. A. (1995). Population characteristics of cyclodextrin complex stabilities in aqueous solution. J. Pharm. Sci., 84, 843-848.
5. Echezarreta-Lopez, M., Torres-Labandeira, J. J., Castineiras-Seijo, L., Santana-Penin, L., & Vila-Jato, J. L. (2000). Complexation of the interferon inducer, bropirimine, with hydroxypropyl-beta-cyclodextrin. Eur. J. Pharm. Sci., 9, 381-386.
6. Frijlink, H. W., Eissens, A. C., Hefting, N. R., Poelstra, K., Lerk, C. F., & Meijer, D. K. (1991). The effect of parenterally administered cyclodextrins on cholesterol levels in the rat. Pharm. Res., 8, 9-16.
7. Gibaud, S., Zirar, S. B., Mutzenhardt, P., Fries, I., & Astier, A. (2005). Melarsoprol-cyclodextrins inclusion complexes. Int. J. Pharm., 306, 107-121.
8. Gladys, G., Claudia, G., & Marcela, L. (2003). The effect of pH and triethanolamine on sulfisoxazole complexation with hydroxypropyl-beta- cyclodextrin. Eur. J. Pharm. Sci., 20, 285-293.
9. Gould, S., & Scott, R. C. (2005). 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): A toxicology review. Food Chem. Toxicol., 43, 1451-1459.
10. Hendriks, H. R., Pizao, P. E., Berger, D. P., Kooistra, K. L., Bibby, M. C., Boven, E., Dreef-van der Meulen HC, Henrar, R. E., Fiebig, H. H., & Double, J. A. (1993). EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur. J. Cancer, 29A, 897-906.
11. Higuchi, T., & Connors, K. A. (1965). Phase-solubility techniques. Adv. Anal. Chem. Instrum., 4, 117-212.
12. Irie, T., & Uekama, K. (1997). Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci., 86, 147-162.
13. Jonkman-de Vries, J. D., Winkelhorst, J., Underberg, W. J. M., Henrar, R. E. C., & Beijnen, J. H. (1993). A systematic study on the chemical stability of the novel indoloquinone antitumor agent EO9. Int. J. of Pharm., 100, 181-188.
14. Loftsson, T., Hreinsdottir, D., & Masson, M. (2005). Evaluation of cyclodextrin solubilization of drugs. Int. J. Pharm., 302, 18-28.
15. McKeown, S. R., Cowen, R. L., & Williams, K. J. (2007). Bioreductive drugs: From concept to clinic. Clin. Oncol. (R. Coll. Radiol.), 19, 427-442.
16. Porras, S. P., Sarmini, K., Fanali, S., & Kenndler, E. (2003). Medium effect (transfer activity coefficient) of methanol and acetonitrile on beta-cyclodextrin/ benzoate complexation in capillary zone electrophoresis. Anal. Chem., 75, 1645-1651.
17. Pralhad, T., & Rajendrakumar, K. (2004). Study of freeze-dried quercetin-cyclodextrin binary systems by DSC, FT-IR, X-ray diffraction and SEM analysis. J. Pharm. Biomed. Anal., 34, 333-339.
18. Rao, V. M., & Stella, V. J. (2003). When can cyclodextrins be considered for solubilization purposes? J. Pharm. Sci., 92, 927-932.
19. Ribeiro, L. S., Ferreira, D. C., & Veiga, F. J. (2003). Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with beta-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur. J. Pharm. Sci., 20, 253-266.
20. Rowe, R. C., Owen, S. C., & Sheskey, P. J. (2006). Handbook of pharmaceutical excipients (5th ed.). London: Pharmaceutical Press.
21. Ruan, L. P., Yu, B. Y., Fu, G. M., & Zhu, D. N. (2005). Improving the solubility of ampelopsin by solid dispersions and inclusion complexes. J. Pharm. Biomed. Anal., 38, 457-464.
22. Szente, L., & Szejtli, J. (1999). Highly soluble cyclodextrin derivatives: Chemistry, properties, and trends in development. Adv Drug Deliv Rev, 36, 17-28.
23. Uekama, K., Hirayama, F., & Irie, T. (1998). Cyclodextrin drug carrier systems. Chem. Rev., 98, 2045-2076.
24. van der Schoot, S. C., Nuijen, B., Flesch, F. M., Gore, A., Mirejovsky, D., Lenaz, L., & Beijnen, J. H. (2007). Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle. AAPS. PharmSciTech., 8, E61.
25. van der Schoot, S. C., Vainchtein, L. D., Beijnen, J. H., Gore, A., Mirejovsky, D., Lenaz, L., & Nuijen, B. (2007). EO-9 bladder instillations: Formulation selection based on stability characteristics and in vitro simulation studies. Int. J. Pharm., 329, 135-141.
26. Veiga, F., Fernandes, C., & Maincent, P. (2001). Influence of the preparation method on the physicochemical properties of tolbutamide/cyclodextrin binary systems. Drug Dev. Ind. Pharm., 27, 523-532.
27. Wen, X., Tan, F., Jing, Z., & Liu, Z. (2004). Preparation and study the 1:2 inclusion complex of carvedilol with beta-cyclodextrin. J. Pharm. Biomed. Anal., 34, 517-523.
28. Zheng, Y., Haworth, I. S., Zuo, Z., Chow, M. S., & Chow, A. H. (2005). Physicochemical and structural characterization of quercetin-beta- cyclodextrin complexes. J. Pharm. Sci., 94, 1079-1089.
29. Zingone, G., & Rubessa, F. (2005). Preformulation study of the inclusion complex warfarin-beta-cyclodextrin. Int. J. Pharm., 291, 3-10.